Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML

Patrick Harrington, Katie J. Doores, Deepti Radia, Amy O’Reilly, Ho Pui Jeff Lam, Jeffrey Seow, Carl Graham, Thomas Lechmere, Donal McLornan, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O’Sullivan, Shahram Kordasti, Michael H. Malim, Claire Harrison, Hugues de Lavallade
doi: https://doi.org/10.1101/2021.04.15.21255482
Patrick Harrington
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
2School of Cancer and Pharmaceutical Science, King’s College London. London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie J. Doores
3Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepti Radia
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy O’Reilly
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ho Pui Jeff Lam
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Seow
3Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Graham
3Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Lechmere
3Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donal McLornan
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
2School of Cancer and Pharmaceutical Science, King’s College London. London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Dillon
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
4Department of Medicine and Molecular Genetics, King’s College London, London. U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yogita Shanmugharaj
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Espehana
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Woodley
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie Saunders
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Curto-Garcia
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer O’Sullivan
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahram Kordasti
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
2School of Cancer and Pharmaceutical Science, King’s College London. London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Malim
3Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Harrison
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
2School of Cancer and Pharmaceutical Science, King’s College London. London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugues de Lavallade
1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
2School of Cancer and Pharmaceutical Science, King’s College London. London, U.K.
5Department of Haematological Medicine, King’s College London School of Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: h.delavallade@nhs.net
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including patients with Chronic Myeloid Leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised.

We evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 CML patients. Seroconversion and cellular immune response prior and after vaccination were assessed.

By day 21 post-vaccination, anti-Spike IgG were detected in 14/16 (87.5%) of CML patients and all developed a neutralizing antibody response (ID50>50), including medium (ID50 of 200-500) or high (501-2000) neutralising antibodies titres in 9/16 (56.25%) patients. T cell response was seen in 14/15 (93.3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response 9/15, polyfunctional CD8+ T cell response 9/15).

These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most CML patients with both neutralizing antibodies and polyfunctional T-cell responses seen, in contrast to patients with solid tumour or lymphoid haematological malignancies.

Funding King’s Together Rapid COVID-19 Call awards to MHM, KJD; A Huo Family Foundation Award to MHM, KJD; Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM; Wellcome Trust Investigator Award 106223/Z/14/Z to MHM; CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to KJD

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Kings Together Rapid COVID19 Call awards to MHM, KJD, A Huo Family Foundation Award to MHM, KJD, Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM, Wellcome Trust Investigator Award 106223/Z/14/Z to MHM, CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1), Fondation Dormeur, Vaduz for funding equipment to KJD

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol (Integrated Research Application System identification number: 285396; Research and Ethics Committe identification number: 20/WM/0187) was reviewed by the West Midlands - Edgbaston Research and Ethics Committee, NHS Health Research Authority, U.K. and the Health Research Authority, Health and Care Research Wales. A favourable opinion was confirmed on 22/6/2020 confirming ethical approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available within the article or its supplementary materials

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 22, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML
Patrick Harrington, Katie J. Doores, Deepti Radia, Amy O’Reilly, Ho Pui Jeff Lam, Jeffrey Seow, Carl Graham, Thomas Lechmere, Donal McLornan, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O’Sullivan, Shahram Kordasti, Michael H. Malim, Claire Harrison, Hugues de Lavallade
medRxiv 2021.04.15.21255482; doi: https://doi.org/10.1101/2021.04.15.21255482
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML
Patrick Harrington, Katie J. Doores, Deepti Radia, Amy O’Reilly, Ho Pui Jeff Lam, Jeffrey Seow, Carl Graham, Thomas Lechmere, Donal McLornan, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O’Sullivan, Shahram Kordasti, Michael H. Malim, Claire Harrison, Hugues de Lavallade
medRxiv 2021.04.15.21255482; doi: https://doi.org/10.1101/2021.04.15.21255482

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9782)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2318)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11656)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2148)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4673)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)